Profound symptomatic bradycardia associated with combined mibefradil and beta-blocker therapy.
We report two cases where the addition of mibefradil to long term beta-blocker therapy in managing hypertension produced profound symptomatic bradycardia requiring cardiac pacing. Reports of a number of interactions between mibefradil and other cardioactive drugs have now led to its withdrawal from the market worldwide.